1. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim H-K, Heinonen E, Ho K, Thorpe R, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29(8):690–3. https://doi.org/10.1038/nbt.1936.
2. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345–52. https://doi.org/10.1038/nri2747.
3. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). European Medicines Agency. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf Accessed 3 Dec 2022.
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations; Guidance for industry. US Food and Drug Administration. 2019. https://www.fda.gov/media/125484/download. Accessed 3 Dec 2022.
5. U.S. Department of Health and Human Services, Food and Drug Administration. Statistical approaches to evaluate analytical similarity; Guidance for industry. US Food and Drug Administration. 2017. https://www.pbwt.com/content/uploads/2018/06/UCM576786.pdf. Accessed 3 Dec 2022.